This article is more than 5 years old. Information may no longer be current.

Ketorolac effective for controlling postop pain after vitreoretinal surgery

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — Ketorolac tromethamine effectively treats postoperative pain following vitreoretinal surgery, according to a study. Compliance with postop procedures in this group of patients may affect surgical outcomes, so pain management is imperative, authors note.

Sharon Fekrat, MD, and colleagues here with Duke University Eye Center and at Baltimore’s Wilmer Eye Center randomized 114 vitreoretinal surgery patients to receive either a single intravenous dose of ketorolac tromethamine or placebo. Postoperative follow-up was at 2 and 5 hours and measured eye pain, nausea and sedation levels.

Patients who received ketorolac were significantly less likely to have postop eye pain. Also, significantly fewer patients in this group required postop analgesia as opposed to patients in the placebo group. While not statistically different, fewer patients in the ketorolac group experienced nausea and sedation.

The study is published in Retina.